Philippe Gabant, PhD

💡 𝗔𝗿𝗲 𝘆𝗼𝘂 𝗿𝗲𝗮𝗱𝘆 𝘁𝗼 𝗲𝘅𝘁𝗲𝗻𝗱 𝘆𝗼𝘂𝗿 𝗱𝗱𝗣𝗖𝗥 𝗸𝗻𝗼𝘄𝗹𝗲𝗱𝗴𝗲?  Fabian Vandermeers will be speaking at the 𝑫𝒓𝒐𝒑𝒍𝒆𝒕 𝑫𝒊𝒈𝒊𝒕𝒂𝒍 𝑷𝑪𝑹 𝑾𝒐𝒓𝒍𝒅 𝑻𝒐𝒖𝒓 in Leuven on November 21. Join him to discover more about 𝐝𝐝𝐂𝐑𝐏 𝐢𝐧 𝐐𝐂 𝐭𝐞𝐬𝐭𝐢𝐧𝐠: 𝐠𝐞𝐧𝐨𝐦𝐞 𝐭𝐢𝐭𝐞𝐫 𝐝𝐞𝐭𝐞𝐫𝐦𝐢𝐧𝐚𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐀𝐀𝐕 𝐬𝐚𝐦𝐩𝐥𝐞𝐬 𝐚𝐧𝐝 𝐫𝐞𝐬𝐢𝐝𝐮𝐚𝐥 𝐂𝐇𝐎 𝐃𝐍𝐀 𝐟𝐨𝐫 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐢𝐞𝐬. It’s still time to register: https://lnkd.in/eSn2RK-k ⚙ The ddPCR is an essential equipment for viral vectors analysis and is used for a wide range of applications, including: 🔹 detection of residual DNA 🔹 quantification of viral load 🔹 determination of the viral vector genome integrity 📥 Download our technical sheet now to learn more about our ddPCR capacity: https://lnkd.in/eNSV3-qw

39

1 Comment

How can we accelerate the delivery of innovative #health techniques and products to patients who need it? By working together to make cell, gene and tissue related therapies available to all European citizens! 💡 That’s why eight European organisations - including flanders.bio - joined forces in the European Hub for Advanced Development in Regenerative Medicine and Biomaterials (EHAB). By building a European interconnected value chain, the #EHAB will identify regional strengths, weaknesses, gaps and needs. 🇪🇺 Stay updated on our progress in strengthening the European landscape in Advanced Therapies and Biomaterials (AT&B) by following the EHAB page! ☝🏼 🫱🏽‍🫲🏾 𝗣𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝗻𝘁𝘀 BOM (Brabantse Ontwikkelings Maatschappij) (🇳🇱) - Brightlands Maastricht Health Campus (🇳🇱) - BioRegio STERN Management GmbH (🇩🇪) - A4TEC Association (🇵🇹) - Biocat, BioRegion of Catalonia (🇪🇸) - RISE Research Institutes of Sweden (🇸🇪) - MedSilesia Cluster - Silesian Medical Devices Network (🇵🇱) - flanders.bio (🇧🇪) 🙌🏽 𝗘𝗻𝗱𝗼𝗿𝘀𝗲𝗿𝘀 Provincie Noord-Brabant - Provincie Limburg - RegMed XB - Departement Economie, Wetenschap en Innovatie (EWI) - Vanguard Initiative - Generalitat de Catalunya - Leitat Technological Center - AseBio - Asociación Española de Bioempresas - Vall d'Hebron Institute of Oncology (VHIO) - Fraunhofer IPA. Funded by the European Union.

36

#BIOMAN4R2 𝙎𝙐𝘾𝘾𝙀𝙎𝙎 𝙎𝙏𝙊𝙍𝙄𝙀𝙎 Discover how our Financial Support Program💰 enables custom, scalable, qualitative and cost-effective cell and gene therapies. ⏩ Check out our #6 Success Story: 🏅 Antleron is one of the awarded companies within the INNOVATION FINANCIAL SUPPORT category. Antleron is a Leuven-based R&D scale-up that develops custom cell-based bioprocess solutions across a wide range of life science applications, with a focus on advanced and personalized therapies, diagnostics and organs-on-chips. Using unique technology toolbox that combines digital twins and 3D printing with the power of cells, the Antleron team of multidisciplinary specialists invents and develops novel biomanufacturing solutions and infrastructure platforms. These solutions will enable next-generation cell and gene therapies to reach patient faster and treat all those in need in a socio-economically more sustainable way. “The BioMan4R2 program enabled us to perform additional validation work for our CellGuide® platform and to extend its use to a new application and customer segment. The BioMan4R2 call provided comprehensible access to EU funding, meeting relevant needs of small companies, such as Antleron. The coordinators from the main office have been helpful throughout the process. The administration required was appropriate for this size of project, letting us focus on the main activity, i.e., delivering innovative solutions for customers active in bioprocesses and biomanufacturing.” We would like to express our gratitude to Antleron for their valuable testimonial. 🙏 Congratulations for your achievements! 🎉 #resilience #europeanunion #biotech #innovation #medicaldevice #EUfunding #medtech #cascadefunding Turku Science Park Ltd Council of European BioRegions - CEBR Biocat, BioRegion of Catalonia BioRegio STERN Management GmbH MedSilesia Cluster - Silesian Medical Devices Network Górnośląski Akcelerator Przedsiębiorczości Rynkowej sp. z o.o. Medicen Paris Region LifetecZONe

20

2 Comments

Poster Presentation Alert! 🚨 On 18 November 2024 at the Antibody Therapeutics Xchange - Brussels 2024 for the Poster Presentation: "Amplifying the therapeutic potential of rabbit antibodies by a multi-parametric humanization approach for single-step engineering" 🐇💉 📌 Register Now to secure your COMPLIMENTARY spot! https://lnkd.in/exN8izkv 💡 Why attend? Rabbit-derived antibodies are powerful, but they need the right engineering for clinical applications. This presentation will showcase cutting-edge strategies, including: 🔬 Early-stage epitope landscape profiling 🖥️ IPA's scalable in silico-driven humanization platform 🧪 High-throughput kinetic profiling for rapid optimization The session will be led by Dr. Ilse Roodink, Ph.D. 🧑‍🔬, CSO of IPA (ImmunoPrecise Antibodies) a global leader in antibody discovery and engineering. Learn how IPA is delivering diverse, optimized antibodies for clinical development with speed and precision! 🗓️ 18 November 2024 | 16:30 - 17:00 | Brussel Don't miss your chance to gain insights into the next-gen humanization techniques for rabbit antibodies. Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #AntibodyDiscovery 🧫 #LeadOptimization ⚙️ #RabbitAntibodies 🐇 #Biotherapeutics 💊 #ClinicalDevelopment 🧬 #LifeSciences 🧑‍🔬 #ImmunoEngineering 🔬 #BiotechInnovations 💡 #Immunoprecise #Biopharma #ScientificRoundtable #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

40

We are delighted to announce that OHMX.bio is now part of the anacura family! 🙌 As a Ghent University spin-off, OHMX.bio has always been at the forefront of advanced -omics technology, specializing in cutting-edge discovery and (pre)clinical studies. Joining forces with anacura, a leader in medical and pharmaceutical analytical services, marks a thrilling expansion of our capabilities and market reach. What this means for our partners and clients: 🔬 Continuation and enhancement of our state-of-the-art next-generation sequencing, advanced bioinformatics, and AI technologies to accelerate discovery and quality control of advanced therapies. 💡 Expanded collaborative opportunities with anacura’s expertise in evidence-based laboratory solutions for healthcare and drug development. 🤝 A shared commitment to quality, scientific excellence, and a personalized approach, ensuring the highest standards of service and innovation. Both anacura’s CEO Griet Nuytinck and our CEO Gerben Menschaert highlight the strategic fit and shared values between the two companies, emphasizing the benefits of combining their expertise and technologies. The acquisition is seen as a way for both companies to grow, innovate, and strengthen their position in the biotech industry, particularly within the Ghent Biotech ecosystem. The entire OHMX.bio team is excited about this new journey. We believe that together with anacura, we will solidify our position as a one-stop shop for clients and a market leader in the Ghent Biotech ecosystem and beyond. Read the full press release through this link: https://lnkd.in/e6GEzHn4 #OHMXbio #Anacura #Acquisition #Biotech #Healthcare #Pharmaceuticals #DrugDiscovery #Diagnostics #Omics

95

19 Comments

𝘽𝙧𝙚𝙖𝙠𝙞𝙣𝙜 𝙉𝙚𝙬𝙨:Bioprex Medical 𝘀𝗲𝗰𝘂𝗿𝗲𝘀 𝗳𝘂𝗻𝗱𝗶𝗻𝗴 𝗳𝗼𝗿 𝗴𝗿𝗼𝘂𝗻𝗱𝗯𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗮𝗻𝘁𝗶𝗯𝗮𝗰𝘁𝗲𝗿𝗶𝗮𝗹 𝗰𝗼𝗮𝘁𝗶𝗻𝗴 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆!🦠 Bioprex Medical, a Groningen-based biotech startup, has successfully closed a new financing round to advance its patented antibacterial coating technology. Over the coming year, Bioprex will focus on preclinical evaluations and expanding collaborations with medical device and implant manufacturers. 𝗞𝗲𝘆 𝗣𝗼𝗶𝗻𝘁𝘀: 𝗙𝘂𝗻𝗱𝗶𝗻𝗴: Led by Pharma Connect Capital and NV NOM. 𝗢𝗯𝗷𝗲𝗰𝘁𝗶𝘃𝗲:Further develop an antibacterial coating to prevent infections caused by medical devices and implants. 𝗙𝗼𝘂𝗻𝗱𝗲𝗱:2022 as a spin-off from the Zernike Institute for Advanced Materials at the University of Groningen. Bioprex's coating, using quaternary ammonium compounds, kills bacteria before they can adhere to surfaces, addressing a major healthcare issue. With over 4 million annual infections in Europe, this technology could greatly reduce infection rates and healthcare costs, especially as antibiotic resistance rises. Bioprex is now focusing on preclinical evaluations, starting with orthopedic implants like pins and screws, and plans to expand to catheters and other devices. 𝗡𝗲𝘅𝘁 𝘀𝘁𝗲𝗽𝘀: Bioprex will focus on preclinical evaluations, starting with orthopedic implants like pins and screws, with plans to expand to catheters and other devices. #dutchinnovation #biotech #startup #healthcare #innovation https://lnkd.in/dEuR8kDt

35

5 Comments

🧬 Are you involved in advanced therapies R&D or related solutions? 🤝 Do you want more visibility to connect with the right investors or partners?   ❗ Then join MEDVIA and BioWin at Advanced Therapies in Belgium, where we focus on cell, gene and other novel therapies 🔥 Register now for a 30% reduction on the ticket fee!   ➡ 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗶𝗻 𝗕𝗲𝗹𝗴𝗶𝘂𝗺 📅 𝟭𝟱 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟮𝟬𝟮𝟰 🗺 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗘𝗰𝗼𝗹𝘆𝘀 𝗩𝗶𝗹𝗹𝗮𝗴𝗲, 𝗡𝗮𝗺𝘂𝗿   WHAT CAN YOU EXPECT? 🧫Plenary session on Belgium’s position in the European ATMP landscape 🧫Debate on major challenges faced by developers of advanced therapies 🧫Presentation of available financing mechanisms 🧫B2B networking & matchmaking 🧫Advanced Therapies Expertise Corner   Sign up to pitch at the event if you have: 🗨️ Project ideas in need of collaboration 🗨️ A track record of joint projects 🗨️ Broad development ideas requiring diverse skills and partners   𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗵𝗲𝗿𝗲 👉🏽 https://lnkd.in/g8CyafGD 𝗣𝗶𝘁𝗰𝗵𝗶𝗻𝗴 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝗺𝗲𝗻𝘁𝘀 👉🏽 https://lnkd.in/e2Tm4NDA #ATMP #AdvancedTherapies #celltherapy #genetherapy #NovelTherapies #healthinnovation #healthtech #medtech #biotech #digitalhealth

15

1 Comment

How can we design more effective T cell therapies? 🤔 Join us for an insightful discussion with Eric de Sousa, Ph.D. candidate and bioinformatician in the Markus Maeurer Lab at the Champalimaud Foundation, for a webinar on June 5th with iRepertoire, Inc.. Eric will present recent data showing differences in TCR repertoires of TILs and their functional phenotypes from various tumor zones. He will also discuss how the TME may impart a particular epigenetic imprint on TILs, information that can be leveraged to develop better cell therapies. Sign up for the webinar today: https://hubs.li/Q02xZXBn0 #TILs #Tcells #TumorMicroenvironment #EpthelialCancer #TcellReceptor #CellTherapy #TCRSequencing #TumorCells #CancerResearch

4

💡 Interested in a fast method to determine the #protein extractability from #potato matrices? #newpublication 📝 We are happy to share our new publication in Food Chemistry by Ben Van den Wouwer, Kristof Brijs, Sebastien Carpentier, Arno Wouters, and Katleen Raes entitled "Extractability and chromatographic separation of proteins from potato (Solanum tuberosum L.) trimmings". 🔎 In this study, size-exclusion HPLC was used to investigate changes in protein extractability from potato trimmings after different pre-treatments. A first step towards the recovery of functional potato proteins from this abundant #food industry by-product. 🍟 👉 Read all about it: https://lnkd.in/e52UHikW 🤝 This work is a collaboration between the Laboratory of Food Chemistry and Biochemistry KU Leuven and VEG-i-TEC (UGent) within the #EffSep project, financially supported by VLAIO - Flanders Innovation & Entrepreneurship and coordinated by Flanders' FOOD. #plantprotein #zerowaste #research #foodchemistry #flandersFOOD #VLAIO KU Leuven Ghent University

36

1 Comment

🚀 Leading the Way in Advanced Therapy Medicinal Products (ATMPs) in Wallonia! At CER Groupe, we're proud to be at the forefront of life sciences innovation in Wallonia, a thriving biotech hub. Belgium's success is fueled by a robust ecosystem, supportive regulatory framework, and strong collaborations between academia and the pharmaceutical industry. Through initiatives like the ATMP-PIT project from Wallonia’s BioWin cluster, we are streamlining the ATMP value chain and pioneering new treatments for complex diseases such as cancer. Special thanks to Service public de Wallonie for their support. Our involvement in the SOLIT project highlights our contribution to the ATMP sector. We are developing orthotopic cancer models for glioblastoma and melanoma, as well as an ICD (Immunogenic Cell Death) model. The goal of the ICD model is turning dying cells into a vaccine. These models will be used to conduct proof-of-concept, efficacy, and safety studies with NOVADIP Biosciences S.A. products, supporting cutting-edge cancer therapies. The project would allow us the development of an innovative platform, aiming at creating unique, and ready-to-use therapeutics targeting solid tumors. A step forward against cancer. Join us in celebrating our commitment to advancing ATMPs and fostering regional growth! See you today at the Advanced Therapies in Belgium. For more details, check out the full article: https://lnkd.in/eMJrSjdY #CERGroupe #ATMP #BiotechInnovation #LifeSciences #CancerResearch #PreclinicalTesting #CellTherapy #GeneTherapy #TumorTargeting  #SOLITProject #MatrisomePlatform  #HealthcareAdvancements #Collaboration  #BelgiumBiotechValley

26

Biotech startup AmphiStar, a leader in sustainable surfactant products, has recently been awarded a €2 million non-dilutive grant from SPRIN-D (Federal Agency for Disruptive Innovation). This brings the total funding secured by the Belgian innovator to €10 million this year. AmphiStar’s biotechnology platform utilizes synthetic biology to develop custom molecules that meet specific performance requirements. These tailor-made biosurfactants, derived from organic waste and side streams, not only provide an environmentally friendly alternative to conventional chemically produced surfactants (fossil- and biobased) and other commercial microbial biosurfactants, but also open up new opportunities for innovation in the cleaning, cosmetics, and personal care industries. Pierre-Franck VALENTIN, Sophie Roelants, Bernd Everaert To share your startup story write us on - [email protected] #Amphistar #biotechnology #Innovation #News #startup #Funding #fundraising https://lnkd.in/gTRfGkeA

33

On 13 May, we took the Antwerp Declaration one step further to discuss the role of biotechnology in boosting Europe’s industrial strategy.    After the incredible support gathered for the Antwerp Declaration for a European Industrial Deal with over 1,100 signatories, Cefic and supporters of the Antwerp Declaration are hosting Antwerp Dialogues. These dialogues bring together different perspectives around one key interest, to collectively foster a deeper understanding of the issue and offer the new policy leaders' recommendations to help shape future policies.      In collaboration with partners like the EFPIA - European Federation of Pharmaceutical Industries and Associations, EuropaBio - the European Association for Bioindustries, and CropLife Europe, our recent dialogue zoomed in on the pivotal role of #biotechnology in Europe's industrial strategy. With our esteemed guests, we dived into questions like:    🔬 How can Europe enhance the agility, speed, and scale of biotechnology innovation?  📈 What industrial targets should Europe aim for to gauge progress in fast-moving global markets?  🔍 What hurdles and tough conversations must we confront to realize EU ambitions?    Stay tuned – the conclusions of this dialogue will be shared soon 🌍     #AntwerpDeclaration #Biotech #euindustry #competitiveness #industrialdeal

102

1 Comment

The conclusions of the Antwerp Dialogue on Biotech are now available ▶ https://lnkd.in/eVCaJr5K This dialogue brought together different viewpoints and emphasised the need for a holistic, ecosystem approach to maximise potential of biotechnology and offered recommendations on: 💶 Mobilising capital and investments 📈 EU measures to stimulate market demand 👷‍♀️ Upskilling and workforce development 💡 Regulatory coherence and predictability 🔎 Scaling up and measuring success We invite you to take a look at the conclusions on the upgraded Antwerp Declaration website 💻  #AntwerpDeclaration #IndustrialDeal   EFPIA - European Federation of Pharmaceutical Industries and Associations, EuropaBio - the European Association for Bioindustries, CropLife Europe, Bayer, dsm-firmenich, Metsä Group, Neste, industriAll Europe

20

🌟 Galapagos, a Flemish biotech company, has made a significant advancement by partnering with Adaptimmune to 𝐝𝐞𝐯𝐞𝐥𝐨𝐩 𝐧𝐞𝐱𝐭-𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐓-𝐜𝐞𝐥𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐢𝐧 𝐚 𝐝𝐞𝐚𝐥 𝐯𝐚𝐥𝐮𝐞𝐝 𝐚𝐭 $𝟔𝟔𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝐛𝐢𝐨𝐛𝐮𝐜𝐤𝐬! This collaboration focuses on uza-cel, a MAGE-A4 TCR T-cell therapy initially designed for ovarian cancer. Galapagos plans to extend its application to head and neck cancer and other solid tumors. 🚀 Dr. Paul Stoffels, MD, Galapagos’ Chief Executive Officer and Chairman, stated: “𝑇ℎ𝑖𝑠 𝑐𝑜𝑙𝑙𝑎𝑏𝑜𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓𝑓𝑒𝑟𝑠 𝑡ℎ𝑒 𝑝𝑟𝑜𝑚𝑖𝑠𝑒 𝑓𝑜𝑟 𝑓𝑎𝑠𝑡𝑒𝑟 𝑎𝑐𝑐𝑒𝑠𝑠 𝑡𝑜 𝑎 𝑝𝑜𝑡𝑒𝑛𝑡𝑖𝑎𝑙𝑙𝑦 𝑡𝑟𝑎𝑛𝑠𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑣𝑒 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡.” 🤝 The funding from this deal ensures the continuation of uza-cel's development and supports the launch of Adaptimmune's leading asset, afami-cel, for synovial sarcoma later this year. Adrian (Ad) Rawcliffe, Adaptimmune’s Chief Executive Officer, noted: “𝐶𝑜𝑚𝑏𝑖𝑛𝑖𝑛𝑔 𝑢𝑧𝑎-𝑐𝑒𝑙 𝑤𝑖𝑡ℎ 𝐺𝑎𝑙𝑎𝑝𝑎𝑔𝑜𝑠’ 𝑢𝑛𝑖𝑞𝑢𝑒 𝑑𝑒𝑐𝑒𝑛𝑡𝑟𝑎𝑙𝑖𝑧𝑒𝑑 𝑚𝑎𝑛𝑢𝑓𝑎𝑐𝑡𝑢𝑟𝑖𝑛𝑔 𝑝𝑙𝑎𝑡𝑓𝑜𝑟𝑚 𝑖𝑠 𝑎 𝑛𝑎𝑡𝑢𝑟𝑎𝑙 𝑠𝑦𝑛𝑒𝑟𝑔𝑦.” 📈 The news has positively impacted Adaptimmune's market performance, with a 21% surge in premarket trading. This collaboration underscores the 𝐢𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐜𝐞 𝐨𝐟 𝐢𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬 𝐢𝐧 𝐚𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐯𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬, celebrated by entities like Flanders Investment & Trade (FIT). 📰: Fierce Biotech, flanders.bio  📸: Labiotech.eu 

146

𝗘𝗻𝗵𝗮𝗻𝗰𝗲 𝘆𝗼𝘂𝗿 𝗺𝗥𝗡𝗔 𝗾𝘂𝗮𝗹𝗶𝘁𝘆: 𝗮𝗰𝗰𝗲𝘀𝘀 𝗼𝘂𝗿 𝗹𝗮𝘁𝗲𝘀𝘁 𝘄𝗵𝗶𝘁𝗲𝗽𝗮𝗽𝗲𝗿𝘀   Since March we launched 4 new whitepapers with the main focus on improving the quality of mRNA and they are still available for free download on our website. Our team of experts, with over 30 years of experience in RNA technology, has poured their expertise into these papers, 𝗼𝗳𝗳𝗲𝗿𝗶𝗻𝗴 𝘆𝗼𝘂 𝗳𝗿𝗲𝘀𝗵 𝗽𝗲𝗿𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲𝘀 𝗮𝗻𝗱 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗺𝗲𝘁𝗵𝗼𝗱𝗼𝗹𝗼𝗴𝗶𝗲𝘀 in:   🥼Utilizing 𝗡𝗲𝘅𝘁-𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 and 𝗧𝗵𝗶𝗿𝗱-𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗦𝗲𝗾𝘂𝗲𝗻𝗰𝗶𝗻𝗴 for RNA Quality Attribute Monitoring by Anna-Marei Böhm 🥼 Why 𝗺𝘂𝗹𝘁𝗶𝗳𝗮𝗰𝗲𝘁𝗲𝗱 𝗽𝗵𝘆𝘀𝗶𝗰𝗼𝗰𝗵𝗲𝗺𝗶𝗰𝗮𝗹 𝗰𝗵𝗮𝗿𝗮𝗰𝘁𝗲𝗿𝗶𝘇𝗮𝘁𝗶𝗼𝗻 is key to ensure the stability of your mRNA-LNP drug product by Sarah Vandenberghe 🥼Improving mRNA Quality by 𝗥𝗲𝗺𝗼𝘃𝗮𝗹 𝗼𝗳 𝗧𝗿𝘂𝗻𝗰𝗮𝘁𝗲𝗱 𝗺𝗥𝗡𝗔 𝗦𝗽𝗲𝗰𝗶𝗲𝘀 by Oligodt Purification by Mateusz Kozarski 🥼 Strengthening 𝗖𝗼𝗻𝘁𝗿𝗼𝗹 𝗼𝗳 𝗗𝗼𝘂𝗯𝗹𝗲-𝗦𝘁𝗿𝗮𝗻𝗱𝗲𝗱 𝗥𝗡𝗔 in mRNA Manufacturing Processes by Senne Dillen   Whether you're in a start-up, early-stage, or late-stage project, our proprietary platforms can support your journey in RNA therapeutics. Dive into our latest research and discover how we can help drive your pipeline development or resolve manufacturing challenges.   Click below to download your copies now and stay ahead in the ever-evolving field of RNA therapeutics! 👉 https://lnkd.in/eyaS-f34

46

**Belgium's Biotech Boom: A Hub of Innovation!** #Belgium is emerging as a European leader in biotechnology, with pioneering companies like Galapagos, argenx, and UCB making significant strides in gene therapy, cancer treatments, and rare diseases. The country's favorable innovation environment attracts investments and talent, reinforcing its global biotech position. Discover how these companies are driving the industry's growth and shaping the future of healthcare. #Biotech #Innovation #Belgium #Healthcare #Technology #Investment Read more Labiotech.eu :

12

BBMRI-ERIC-nl at the symposium for ELSI insights & outlook for biobanks and medical research: Earlier this month BBMRI-nl took part in the Symposium for Ethical, Legal and Societal Insights (ELSI) & outlook for biobanks and medical research in Lyon, co-organised by BBMRI-ERIC. The symposium brought together #ELSI and biobank experts from across Europe and even abroad.     From BBMRI-nl, a representative from the national ELSI Servicedesk and Health-RI ELSI team participated. Miriam Beusink provided insight into the Dutch consent procedures for reusing health data and samples in research: the current situation, showcasing the broad consent of the Netherlands Cancer Institute and diving into the potential bias this is causing, as well as Health-RI's desire to create a national consent registry. Other discussed topics were the #EHDS, the importance of knowing the context of the data for responsible secondary use, the importance of being able to clearly communicate with patients and citizens, trust, anonymity, return of results and incidental findings, and problems around data integration and large data infrastructures.  The Dutch node (BBMRI-nl) of the European Research Infrastructure BBMRI is hosted by Health-RI. For more information visit https://lnkd.in/eDD9ruid

51

30 % of medicines under development target #rarediseases. In #Belgium, only a limited number of rare disease #treatments are reimbursed. The share is even 15 % lower than six years ago! An alarming situation... See the latest info here: NL: https://lnkd.in/eZvUPWb9 FR: https://lnkd.in/eejtMTaV #zeldzameziekten #maladiesrares #gezondheid #santé #research #onderzoek #recherche #geneesmiddelen #vaccins #médicaments #patiënten #patients #België #Belgique RARE DISEASES ORGANISATION BELGIUM Eva Schoeters Filipo Serra Hanne Wouters Marjan Willaert Patricia van Dijck @eurodis EFPIA - European Federation of Pharmaceutical Industries and Associations #médicamentsorphelins #weesgeneesmiddelen RIZIV-INAMI

44